ʻO kahi haʻawina hui pū ʻia e ka ʻO Monash Biomedicine Discovery Institute (BDI) me ka Peter Doherty Institute of Infection and Immunity (Doherty Institute), kahi hui pū ʻia o ke Kulanui o Melbourne a me ka Haukapila Royal Melbourne, ua hōʻike ʻia ua loaʻa kahi lāʻau anti-parasite ma ka honua holoʻokoʻa i ka maʻi ma loko o 48 mau hola.

ʻOiai ke hoʻomaka ʻia nei nā hoʻokolohua hoʻokolohua e hoʻāʻo i nā therapies hiki, ka palena o ka pane honua i ka maʻi COVID-19 i kaupalena ʻia i ka nānā ʻana / kaohi. ʻO Ivermectin, kahi anti-parasitic i ʻae ʻia e FDA i hōʻike ʻia ma mua i loaʻa i ka laulā-19 spectrum anti-viral activity in vitro, kahi mea kāohi i ka maʻi hoʻomaʻamaʻa.

ʻO ka hoʻohana ʻana o Ivermectin e hakakā me COVID-19 kaukaʻi ʻia i ka hoʻokolohua mua a me nā hoʻokolohua hoʻokolohua, me ke kālā e koi nui ʻia e holomua i ka hana.

Ma Australia, ua paʻi ʻia kahi noiʻi hui pū ʻia e Monash University i alakaʻi ʻia ma ʻImi Antiviral, kahi puke pai olakino loiloi ʻia e nā hoa https://doi.org/10.1016/j.antiviral.2020.104787

ʻO ka Monash Biomedicine Discovery Institute's ʻO Dr Kylie Wagstaff, nāna i alakaʻi ke aʻo ʻana, ua hōʻike nā ʻepekema ua hōʻike ka lāʻau lapaʻau, ʻo Ivermectin, i ka maʻi maʻi SARS-CoV-2 e ulu nei i ka moʻomeheu o ka paʻa ma loko o 48 mau hola.

"Ua ʻike mākou he hiki i kahi mahele lāʻau hoʻokahi ke hoʻoneʻe i nā viral RNA āpau e 48 mau hola a ʻoiai ma 24 mau hola he hōʻemi nui maoli ia i loko," wahi a Dr Wagstaff.

ʻO Ivermectin kahi lāʻau ʻae anti-parasitic i ʻae ʻia e FDA i hōʻike ʻia he mana ma ka vitro e kūʻē ana i kahi ākea o nā maʻi e like me HIV, Dengue, Influenza a me Zika virus.

Ua aʻo aku ʻo Dr Wagstaff ʻo nā hoʻokolohua i mālama ʻia i loko o ke aʻo ʻana ma ka vitro a pono e hoʻokō ʻia nā hoʻokolokolo i loko o nā kānaka.

"Hoʻohana nui ʻia ʻo Ivermectin a ʻike ʻia ma ke ʻano he lāʻau palekana. Pono mākou e noʻonoʻo i kēia manawa inā paha e maikaʻi ke ana i hiki ai iā ʻoe ke hoʻohana i loko o ke kanaka - ʻo ia ka hana aʻe, ”i ʻōlelo ʻo Dr Wagstaff.

"I nā manawa ke loaʻa nei mākou i kahi maʻi ahulau āpau a ʻaʻohe ʻaelike i ʻae ʻia, inā he mea hoʻohui kā mākou i loaʻa a puni ka honua a laila e kōkua paha i ka poʻe ma mua koke. ʻOiaʻiʻo he manawa ia ma mua o ka loaʻa ākea o kahi lāʻau āpau.

ʻOiai ʻaʻole ʻike ʻia ka mīkini a Ivermectin e hana ai i ka maʻi, aia paha ia, ma muli o kāna hana i nā maʻi ʻē aʻe, hana ia e hoʻopau i ka maʻi e hoʻoliʻiliʻi 'ana i ka hiki i nā pūnaewele host ke hoʻomaʻemaʻe iā ia, wahi a Dr Wagstaff.

ʻO ka Haukapila ʻo Royal Melbourne ʻo Dr Leon Caly, he ʻepekema ʻepekema kiʻekiʻe ma ka Victorian Infectious Diseases Reference Laboratory (VIDRL) ma ka Doherty Institute kahi i mālama ʻia ai nā hoʻokolohua me ka coronavirus ola, ʻo ia ka mea kākau mua o ke aʻo.

"Ma ke ʻano he virologist i ʻāpana o ka hui i hoʻokaʻawale mua a kaʻana like iā SARS-COV2 ma waho o Kina i Ianuali 2020, hauʻoli wau e pili ana i ka prospect o Ivermectin e hoʻohana ʻia e like me kahi lāʻau hiki ke kūʻē iā COVID-19," wahi a Dr Caly. .

Ua hana ʻo Dr Wagstaff i kahi ʻike breakthrough mua ma Ivermectin i ka makahiki 2012 i kona ʻike ʻana i ka lāʻau a me kāna hana antiviral me Monash Biomedicine Discovery Institute's ʻO Polofesa David Jans, kekahi mea kākau ma kēia pepa. Ke ʻimi nei ʻo Professor Jans a me kāna hui iā Ivermectin no 10 mau makahiki me nā virus like ʻole.

Hoʻomaka ʻo Dr Wagstaff lāua ʻo Professor Jans e hoʻokolokolo inā hana paha ia i ka maʻi SARS-CoV-2 ke ʻike ʻia ka hoʻomaka ʻana o ka maʻi ahulau.

ʻO ka hoʻohana ʻana o Ivermectin e hakakā me COVID-19 kaukaʻi ʻia i nā hopena o ka hoʻokolohua mua loa ʻana a me nā hoʻokolohua hoʻokolohua hope loa, me ke kālā e koi nui ʻia e hoʻomau i ka holomua o ka hana, i ʻōlelo ʻo Dr Wagstaff.

E heluhelu i ka pepa piha i ka Antiviral Research me ke poʻo inoa: ʻO ka Ivermectin i ʻāpono ʻia e FDA e kāohi i ka hana hou ʻana o SARS-CoV-2 i vitro

I kēia manawa, ʻimi ʻimi ʻia kekahi mau lāʻau ʻē aʻe he 40 no nā pōmaikaʻi e mālama iā COVID-19.

He aha e lawe ʻia mai kēia ʻatikala:

Although the mechanism by which Ivermectin works on the virus is not known, it is likely, based on its action in other viruses, that it works to stop the virus ‘dampening down' the host cells' ability to clear it, Dr Wagstaff said.
"Ma ke ʻano he virologist i ʻāpana o ka hui i hoʻokaʻawale mua a kaʻana like iā SARS-COV2 ma waho o Kina i Ianuali 2020, hauʻoli wau e pili ana i ka prospect o Ivermectin e hoʻohana ʻia e like me kahi lāʻau hiki ke kūʻē iā COVID-19," wahi a Dr Caly. .
A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint venture of the University of Melbourne and Royal Melbourne Hospital, has shown that an anti-parasitic drug already available around the world kills the virus within 48 hours.